Esperion Therapeutics
ESPR
ESPR
122 hedge funds and large institutions have $75.9M invested in Esperion Therapeutics in 2023 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 36 increasing their positions, 31 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
2% less funds holding
Funds holding: 124 → 122 (-2)
6.31% less ownership
Funds ownership: 78.54% → 72.23% (-6.3%)
27% less capital invested
Capital invested by funds: $104M → $75.9M (-$27.7M)
Holders
122
Holding in Top 10
2
Calls
$1.67M
Puts
$335K
Top Buyers
| 1 | +$4.64M | |
| 2 | +$2.4M | |
| 3 | +$1.8M | |
| 4 |
JPMorgan Chase & Co
New York
|
+$1.61M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$1.23M |
Top Sellers
| 1 | -$12.8M | |
| 2 | -$1.84M | |
| 3 | -$1.58M | |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
-$1.25M |
| 5 |
MG
Meditor Group
Hamilton,
Bermuda
|
-$599K |